Hepatopulmonary shunting: A prognostic indicator of survival in patients with metastatic colorectal adenocarcinoma treated with 90Y radioembolization

Radiology

Volumn 282, Issue 1, 2017, Pages 281-288

  Narsinh, Kazim H ^a   Van Buskirk, Mark ^b   Kennedy, Andrew S ^c   Suhail, Mohammed ^a   Alsaikhan, Naif ^a   Hoh, Carl K ^a   Thurston, Kenneth ^d   Minocha, Jeet ^a   Ball, David S ^e   Cohen, Steven J ^e   Cohn, Michael ^f   Coldwell, Douglas M ^g   Drooz, Alain ^h   Ehrenwald, Eduardo ⁱ   Kanani, Samir ^j   Nutting, Charles W ^k   Moeslein, Fred M ^l   Savin, Michael A ^m   Schirm, Sabine ⁿ   Putnam, Samuel G ^e   Sharma, Navesh K ^l   Wang, Eric A ^m   Rose, Steven C ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b Data Reduction   (United States)

^c SARAH CANNON RESEARCH INSTITUTE   (United States)

^d Sirtex Medical   (United States)

^e FOX CHASE CANCER CENTER   (United States)

^f Radiologic Assoct of Hollywood   (United States)

^g UNIVERSITY OF LOUISVILLE   (United States)

^h Fairfax Radiological Consultants   (United States)

ⁱ ABBOTT NORTHWESTERN HOSPITAL   (United States)

^j INOVA FAIRFAX HOSPITAL   (United States)

^k Department of Interventional Neuroradiology Radiology Imaging Assoct   (United States)

^l UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^m BEAUMONT HOSPITAL   (United States)

ⁿ Cancer Ctrs of North Carolina   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; BILIRUBIN; CARCINOEMBRYONIC ANTIGEN; MACROSALB TC 99M; YTTRIUM 90; MICROSPHERE; YTTRIUM;

ADULT; ARTICLE; ASCITES; BILIRUBIN BLOOD LEVEL; BRACHYTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; EMBOLIC PARTICLE; FEMALE; HAZARD RATIO; HEPATOPULMONARY SHUNTING; HUMAN; LIVER ANGIOGRAPHY; LIVER WEIGHT; LUNG SHUNT FRACTION; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; RADIOEMBOLIZATION; RETROSPECTIVE STUDY; SHUNTING; SURVIVAL TIME; ADENOCARCINOMA; AGED; ANGIOGRAPHY; ARTERIOVENOUS FISTULA; ARTIFICIAL EMBOLIZATION; CLINICAL TRIAL; COLORECTAL NEOPLASMS; COMPLICATION; DIAGNOSTIC IMAGING; LIVER; LUNG; MIDDLE AGED; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PROCEDURES; PROGNOSIS; SURVIVAL RATE; TREATMENT OUTCOME; VASCULARIZATION; X-RAY COMPUTED TOMOGRAPHY;

ADENOCARCINOMA; ADULT; AGED; ANGIOGRAPHY; ARTERIOVENOUS FISTULA; COLORECTAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER; LUNG; MAGNETIC RESONANCE IMAGING; MALE; MICROSPHERES; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; YTTRIUM RADIOISOTOPES;

EID: 85007524509     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.2016152100     Document Type: Article

References (25)

1. Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol 2009;6(12):687-697.
2. Kennedy A. Radioembolization of hepatic tumors. J Gastrointest Oncol 2014;5(3):178-189.
3. Kennedy A, Coldwell D, Sangro B, Wasan H, Salem R. Integrating radioembolization ((90)Y microspheres) into current treatment options for liver tumors: introduction to the international working group report. Am J Clin Oncol 2012;35(1):81-90.
4. Ngan H, Peh WC. Arteriovenous shunting in hepatocellular carcinoma: its prevalence and clinical significance. Clin Radiol 1997;52(1): 36-40.
5. Honda H, Tajima T, Kajiyama K, et al. Vascular changes in hepatocellular carcinoma: correlation of radiologic and pathologic findings. AJR Am J Roentgenol 1999;173(5):1213-1217.
6. Leung TW, Lau WY, Ho SK, et al. Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys 1995;33(4):919-924.
7. Leung WT, Lau WY, Ho SK, et al. Measuring lung shunting in hepatocellular carcinoma with intrahepatic-arterial technetium-99m macroaggregated albumin. J Nucl Med 1994;35(1):70-73.
8. Kennedy A, Nag S, Salem R, et al. Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: A consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys 2007;68(1):13-23.
9. Deipolyi AR, Iafrate AJ, Zhu AX, Ergul EA, Ganguli S, Oklu R. High lung shunt fraction in colorectal liver tumors is associated with distant metastasis and decreased survival. J Vasc Interv Radiol 2014;25(10):1604-1608.
10. Kennedy AS, Ball D, Cohen SJ, et al. Multicenter evaluation of the safety and efficacy of radioembolization in patients with unresectable colorectal liver metastases selected as candidates for (90)Y resin microspheres. J Gastrointest Oncol 2015;6(2):134-142.
11. Salem R, Thurston KG. Radioembolization with 90yttrium microspheres: A state-ofthe-art brachytherapy treatment for primary and secondary liver malignancies. Part 1: technical and methodologic considerations. J Vasc Interv Radiol 2006;17(8): 1251-1278.
12. Wright CL, Werner JD, Tran JM, et al. Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Interv Radiol 2012;23(5): 669-674.
13. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999;230(3):309-318; discussion 318-321.
14. Shady W, Petre EN, Gonen M, et al. Percutaneous radiofrequency ablation of colorectal cancer liver metastases: factors affecting outcomes - A 10-year experience at a single center. Radiology 2016;278(2):601-611.
15. Rees M, Tekkis PP, Welsh FKS, O'Rourke T, John TG. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: A multifactorial model of 929 patients. Ann Surg 2008;247(1):125-135.
16. Sofocleous CT, Violari EG, Sotirchos VS, et al. Radioembolization as a salvage therapy for heavily pretreated patients with colorectal cancer liver metastases: factors that affect outcomes. Clin Colorectal Cancer 2015;14(4):296-305.
17. Xing M, Lahti S, Kokabi N, Schuster DM, Camacho JC, Kim HS. 90Y radioembolization lung shunt fraction in primary and metastatic liver cancer as a biomarker for survival. Clin Nucl Med 2016;41(1):21-27.
18. Ho S, Lau WY, Leung WT, et al. Arteriovenous shunts in patients with hepatic tumors. J Nucl Med 1997;38(8):1201-1205.
19. Powerski MJ, Erxleben C, Scheurig-Münkler C, et al. Hepatopulmonary shunting in patients with primary and secondary liver tumors scheduled for radioembolization. Eur J Radiol 2015;84(2):201-207.
20. Salem R, Parikh P, Atassi B, et al. Incidence of radiation pneumonitis after hepatic intra-arterial radiotherapy with yttrium-90 microspheres assuming uniform lung distribution. Am J Clin Oncol 2008;31(5):431-438.
21. Lam MGEH, Banerjee A, Goris ML, et al. Fusion dual-tracer SPECT-based hepatic dosimetry predicts outcome after radioembolization for a wide range of tumour cell types. Eur J Nucl Med Mol Imaging 2015;42(8): 1192-1201.
22. Bester L, Salem R. Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vasc Interv Radiol 2007;18(10): 1310-1314.
23. Rose SC, Hoh CK. Hepatopulmonary shunt reduction using chemoembolization to permit yttrium-90 radioembolization. J Vasc Interv Radiol 2009;20(6):849-851.
24. Ward TJ, Tamrazi A, Lam MG, et al. Management of high hepatopulmonary shunting in patients undergoing hepatic radioembolization. J Vasc Interv Radiol 2015;26(12):1751-1760.
25. Bourgeois AC, Chang TT, Bradley YC, Acuff SN, Pasciak AS. Intraprocedural yttrium-90 positron emission tomography/CT for treatment optimization of yttrium-90 radioembolization. J Vasc Interv Radiol 2014; 25(2):271-275.